|
|
|
|
| LEADER |
01284cas a2200325 a 4500 |
| 001 |
8916560 |
| 003 |
DNLM |
| 005 |
20130509061741.0 |
| 008 |
891012c19849999maumr p 0 0eng |
| 022 |
|
|
|a 0749-5005
|l 0749-5005
|
| 035 |
|
|
|a (DNLM)SR0065302(s)
|
| 035 |
|
|
|a (OCoLC)11136422
|
| 040 |
|
|
|a DNLM
|c DNLM
|
| 060 |
0 |
0 |
|a W1
|b U8305
|
| 222 |
|
0 |
|a U.S. regulatory reporter
|
| 245 |
0 |
0 |
|a U.S. regulatory reporter.
|
| 260 |
|
|
|a Cambridge, Mass. :
|b Parexel International Corp.,
|
| 300 |
|
|
|a v.
|
| 310 |
|
|
|a Monthly
|
| 500 |
|
|
|a Vols. for May 1989?- have pull out sections: Regulatory review, Congressional monitor, and Biologics and biotech regulatory report.
|
| 500 |
|
|
|a Description based on: Vol. 1, no. 4 (Sept. 1984); title from caption.
|
| 650 |
|
2 |
|a Drug Evaluation
|x standards
|z United States
|v Periodicals.
|
| 650 |
|
2 |
|a Drug Industry
|x standards
|z United States
|v Periodicals.
|
| 650 |
|
2 |
|a Legislation, Drug
|z United States
|v Periodicals.
|
| 710 |
2 |
|
|a Parexel International Corporation.
|
| 730 |
0 |
|
|a Regulatory review.
|
| 730 |
0 |
|
|a Congressional monitor.
|
| 730 |
0 |
|
|a Biologics and biotech regulatory report.
|
| 999 |
|
|
|c 72520
|d 72520
|
| 952 |
|
|
|0 0
|1 0
|4 0
|7 0
|9 813437
|a M-BNCS
|b M-BNCS
|h 1990(1991)1992-2000.
|o M-BNCS-813437JNL-0749-5005
|p M-BNCS-813437JNL-72520
|t 1116208
|y JNL
|
